Venous thromboembolism ( VTE ), comprising deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ), represents a significant public health and financial burden. The launch of non-vitamin K antagonist oral anticoagulants ( NOAC s) for VTE is addressing the need for more-convenient alternatives compared with long-established therapies, and these agents will drive market growth in the near to mid term. Toward the end of our forecast period, generic NOAC s will be widely available, and the VTE market will enter a new phase of evolution. There are still considerable areas of unmet need within VTE , such as the primary prophylaxis of VTE in acute medically ill patients and ambulatory cancer patients. The ongoing label expansion program for the NOAC s and emerging therapies such as betrixaban and IONIS-FXIRx offer potential solutions to these unmet needs.<\/p>\n
\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-390807","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-venous-thromboembolism","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390807\/revisions"}],"predecessor-version":[{"id":393931,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390807\/revisions\/393931"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}